Chapter 189 |
2016 -- H 7616 SUBSTITUTE A Enacted 06/28/2016 |
A N A C T |
RELATING TO HEALTH AND SAFETY -- INSURANCE--MENTAL ILLNESS AND SUBSTANCE ABUSE |
Introduced By: Representatives Bennett, Hull, Casey, Slater, and Diaz |
Date Introduced: February 12, 2016 |
It is enacted by the General Assembly as follows: |
SECTION 1. Section 23-17.26-3 of the General Laws in Chapter 23-17.26 entitled |
"Comprehensive Discharge Planning" is hereby amended to read as follows: |
23-17.26-3. Comprehensive discharge planning. -- (a) On or before July 1, 2015 |
January 1, 2017, each hospital and freestanding, emergency-care facility operating in the Sstate of |
Rhode Island shall submit to the director a comprehensive discharge plan that includes: |
(1) Evidence of participation in a high-quality, comprehensive discharge-planning and |
transitions-improvement project operated by a nonprofit organization in this state; or |
(2) A plan for the provision of comprehensive discharge planning and information to be |
shared with patients transitioning from the hospitals hospital's or freestanding, emergency-care |
facility's care. Such plan shall contain the adoption of evidence-based practices including, but not |
limited to: |
(i) Providing in-hospital education in the hospital or freestanding, emergency-care facility |
prior to discharge; |
(ii) Ensuring patient involvement such that, at discharge, patients and caregivers |
understand the patient's conditions and medications and have a point of contact for follow-up |
questions; |
(iii) With patient consent, attempting to notify the person(s) listed as the patient's |
emergency contacts and recovery coach before discharge. If the patient refuses to consent to the |
notification of emergency contacts, such refusal shall be noted in the patient's medical record; |
(iii)(iv) Attempting to identify patients' primary care providers and assisting with |
scheduling post-hospital post-discharge follow-up appointments prior to patient discharge; |
(iv)(v) Expanding the transmission of the department of health's continuity-of-care form, |
or successor program, to include primary care providers' receipt of information at patient |
discharge when the primary care provider is identified by the patient; and |
(v)(vi) Coordinating and improving communication with outpatient providers. |
(3) The discharge plan and transition process shall also be made include recovery |
planning tools for patients with opioid and other substance use disorders substance-use disorders, |
opioid overdoses, and chronic addiction, which plan and transition process shall include the |
elements contained in subsections (a)(1) or (a)(2) of this section, as applicable. In addition, such |
discharge plan and transition process shall also include: |
(i) Assistance, with patient consent, in securing at least one follow-up appointment for |
the patient within seven (7) days of discharge, as clinically appropriate: (A) With a facility |
licensed by the department of behavioral healthcare, developmental disabilities and hospitals to |
provide treatment of substance use disorders; (B) With a certified recovery coach; (C) With a |
licensed clinician with expertise in the treatment of substance use disorders; or (D) With a Rhode |
Island licensed hospital with a designated program for the treatment of substance use disorders. |
The patient shall be informed of said appointment prior to the patient being discharged from the |
hospital; |
(ii) In the absence of a scheduled follow-up appointment pursuant to subsection (a)(3)(i), |
every reasonable effort shall be made to contact the patient within thirty (30) days post-discharge |
to provide the patient with a referral and other such assistance as the patient needs to obtain a |
follow-up appointment; and |
(iii) That the patient receives information about the real-time availability of appropriate |
in-patient and out-patient services in Rhode Island. |
(i) That, with patient consent, each patient presenting to a hospital or freestanding, |
emergency-care facility with indication of a substance-use disorder, opioid overdose, or chronic |
addiction shall receive a substance-abuse evaluation, in accordance with the standards in |
subsection (a)(4)(ii), before discharge. Prior to the dissemination of the standards in subsection |
(a)(4)(ii), with patient consent, each patient presenting to a hospital or freestanding, emergency- |
care facility with indication of a substance-use disorder, opioid overdose, or chronic addiction |
shall receive a substance-abuse evaluation, in accordance with best practices standards, before |
discharge; |
(ii) That if, after the completion of a substance-abuse evaluation, in accordance with the |
standards in subsection (a)(4)(ii), the clinically appropriate inpatient and outpatient services for |
the treatment of substance-use disorders, opioid overdose, or chronic addiction contained in |
subsection (a)(3)(iv) are not immediately available, the hospital or freestanding, emergency-care |
facility shall provide medically necessary and appropriate services with patient consent, until the |
appropriate transfer of care is completed; |
(iii) That, with patient consent, pursuant to 21 C.F.R. ยง1306.07, a physician in a hospital |
or freestanding, emergency-care facility, who is not specifically registered to conduct a narcotic |
treatment program, may administer narcotic drugs, including buprenorphine, to a person for the |
purpose of relieving acute, opioid-withdrawal symptoms, when necessary, while arrangements |
are being made for referral for treatment. Not more than one day's medication may be |
administered to the person or for the person's use at one time. Such emergency treatment may be |
carried out for not more than three (3) days and may not be renewed or extended; |
(iv) That each patient presenting to a hospital or freestanding, emergency-care facility |
with indication of a substance-use disorder, opioid overdose, or chronic addiction, shall receive |
information, made available to the hospital or freestanding, emergency-care facility in accordance |
with subsection (a)(4)(v), about the availability of clinically appropriate inpatient and outpatient |
services for the treatment of substance-use disorders, opioid overdose, or chronic addiction, |
including: |
(A) Detoxification; |
(B) Stabilization; |
(C) Medication-assisted treatment or medication-assisted maintenance services, including |
methadone, buprenorphine, naltrexone, or other clinically appropriate medications; |
(D) Inpatient and residential treatment; |
(E) Licensed clinicians with expertise in the treatment of substance-use disorders, opioid |
overdoses, and chronic addiction; |
(F) Certified recovery coaches; and |
(v) That, when the real-time patient services database outlined in subsection (a)(4)(vi) |
becomes available, each patient shall receive real-time information from the hospital or |
freestanding, emergency-care facility about the availability of clinically appropriate inpatient and |
outpatient services. |
(4) On or before November 1, 2014 January 1, 2017, the director of the department of |
health, shall develop and disseminate to all hospitals, health care clinics, urgent care centers, and |
emergency room diversion facilities a model discharge plan and transition process for patients |
with opioid and other substance use disorders. This model plan may be used as a guide, but may |
be amended and modified to meet the specific needs of each hospital, health care clinic, urgent |
care center and emergency room diversion facility. with the director of the department of |
behavioral healthcare, developmental disabilities and hospitals, shall: |
(i) Develop and disseminate, to all hospitals and freestanding, emergency-care facilities, a |
regulatory standard for the early introduction of a recovery coach during the pre-admission and/or |
admission process for patients with substance-use disorders, opioid overdose, or chronic |
addiction; |
(ii) Develop and disseminate, to all hospitals and freestanding, emergency-care facilities, |
substance-abuse evaluation standards for patients with substance-use disorders, opioid overdose, |
or chronic addiction; |
(iii) Develop and disseminate, to all hospitals and freestanding, emergency-care facilities, |
pre-admission, admission, and discharge regulatory standards, a recovery plan, and voluntary |
transition process for patients with substance-use disorders, opioid overdose, or chronic addiction. |
Recommendations from the 2015 Rhode Island governor's overdose prevention and intervention |
task force strategic plan may be incorporated into the standards as a guide, but may be amended |
and modified to meet the specific needs of each hospital and freestanding, emergency-care |
facility; |
(iv) Develop and disseminate best practices standards for health care clinics, urgent-care |
centers, and emergency-diversion facilities regarding protocols for patient screening, transfer, and |
referral to clinically appropriate inpatient and outpatient services contained in subsection |
(a)(3)(iv); |
(v) Develop regulations for patients presenting to hospitals and freestanding, emergency- |
care facilities with indication of a substance-use disorder, opioid overdose, or chronic addiction to |
ensure prompt, voluntary access to clinically appropriate inpatient and outpatient services |
contained in subsection (a)(3)(iv); |
(vi) Develop a strategy to assess, create, implement, and maintain a database of real-time |
availability of clinically appropriate inpatient and outpatient services contained in subsection |
(a)(3)(iv) of this section on or before January 1, 2018. |
SECTION 2. Section 27-38.2-1 of the General Laws in Chapter 27-38.2 entitled |
"Insurance Coverage for Mental Illness and Substance Abuse" is hereby amended to read as |
follows: |
27-38.2-1. Coverage for the treatment of mental health and substance use disorders.. |
-- (a) A group health plan and an individual or group health insurance plan shall provide coverage |
for the treatment of mental health and substance-use disorders under the same terms and |
conditions as that coverage is provided for other illnesses and diseases. |
(b) Coverage for the treatment of mental health and substance-use disorders shall not |
impose any annual or lifetime dollar limitation. |
(c) Financial requirements and quantitative treatment limitations on coverage for the |
treatment of mental health and substance-use disorders shall be no more restrictive than the |
predominant financial requirements applied to substantially all coverage for medical conditions in |
each treatment classification. |
(d) Coverage shall not impose non-quantitative treatment limitations for the treatment of |
mental health and substance-use disorders unless the processes, strategies, evidentiary standards, |
or other factors used in applying the non-quantitative treatment limitation, as written and in |
operation, are comparable to, and are applied no more stringently than, the processes, strategies, |
evidentiary standards, or other factors used in applying the limitation with respect to |
medical/surgical benefits in the classification. |
(e) The following classifications shall be used to apply the coverage requirements of this |
chapter: (1) Inpatient, in-network; (2) Inpatient, out-of-network; (3) Outpatient, in-network; (4) |
Outpatient, out-of-network; (5) Emergency care; and (6) Prescription drugs. |
(f) Medication-assisted therapy including methadone, treatment or medication-assisted |
maintenance services of substance-use disorders, opioid overdoses, and chronic addiction, |
including methadone, buprenorphine, naltrexone, or other clinically appropriate medications, |
maintenance services, for the treatment of substance-use disorders, opioid overdoses, and chronic |
addiction is included within the appropriate classification based on the site of the service. |
(g) Payors shall rely upon the criteria of the American Society of Addiction Medicine |
when developing coverage for levels of care for substance-use disorder treatment. |
SECTION 3. This act shall take effect upon passage. |
======== |
LC004901/SUB A |
======== |